Evidence map›Paper›PMID 39835290›Full record

ReviewFrontiers in cellular neuroscience2024

Advances in physiological and clinical relevance of hiPSC-derived brain models for precision medicine pipelines.

Negin Imani Farahani, Lisa Lin, Shama Nazir, Alireza Naderi, Leanne Rokos, Anthony Randal McIntosh, Lisa M Julian

Abstract readReview
In one paragraph

Review in Frontiers in cellular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Negin Imani FarahaniDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Lisa LinCentre for Cell Biology, Development, and Disease, Simon Fraser University, Burnaby, BC, Canada.
Shama NazirCentre for Cell Biology, Development, and Disease, Simon Fraser University, Burnaby, BC, Canada.
Alireza NaderiCentre for Cell Biology, Development, and Disease, Simon Fraser University, Burnaby, BC, Canada.
Leanne RokosInstitute for Neuroscience and Neurotechnology, Simon Fraser University, Burnaby, BC, Canada.
Anthony Randal McIntoshInstitute for Neuroscience and Neurotechnology, Simon Fraser University, Burnaby, BC, Canada.
Lisa M JulianDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision, or personalized, medicine aims to stratify patients based on variable pathogenic signatures to optimize the effectiveness of disease prevention and treatment. This approach is favorable in the context of brain disorders, which are often heterogeneous in their pathophysiological features, patterns of disease progression and treatment response, resulting in limited therapeutic standard-of-care. Here we highlight the transformative role that human induced pluripotent stem cell (hiPSC)-derived neural models are poised to play in advancing precision medicine for brain disorders, particularly emerging innovations that improve the relevance of hiPSC models to human physiology. hiPSCs derived from accessible patient somatic cells can produce various neural cell types and tissues; current efforts to increase the complexity of these models, incorporating region-specific neural tissues and non-neural cell types of the brain microenvironment, are providing increasingly relevant insights into human-specific neurobiology. Continued advances in tissue engineering combined with innovations in genomics, high-throughput screening and imaging strengthen the physiological relevance of hiPSC models and thus their ability to uncover disease mechanisms, therapeutic vulnerabilities, and tissue and fluid-based biomarkers that will have real impact on neurological disease treatment. True physiological understanding, however, necessitates integration of hiPSC-neural models with patient biophysical data, including quantitative neuroimaging representations. We discuss recent innovations in cellular neuroscience that can provide these direct connections through generative AI modeling. Our focus is to highlight the great potential of synergy between these emerging innovations to pave the way for personalized medicine becoming a viable option for patients suffering from neuropathologies, particularly rare epileptic and neurodegenerative disorders.

Indexed as

biomarkersbrain disordersbrain organoidsgenerative AIhiPSCsneurophysiologyprecision medicine

Identifiers

PMID39835290
PMCPMC11743572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.